186 related articles for article (PubMed ID: 7565456)
1. A small dose of human parathyroid hormone(1-34) increased bone mass in the lumbar vertebrae in patients with senile osteoporosis.
Sone T; Fukunaga M; Ono S; Nishiyama T
Miner Electrolyte Metab; 1995; 21(1-3):232-5. PubMed ID: 7565456
[TBL] [Abstract][Full Text] [Related]
2. Bone mass continues to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoid-induced osteoporosis: results of a randomized controlled clinical trial.
Lane NE; Sanchez S; Modin GW; Genant HK; Pierini E; Arnaud CD
J Bone Miner Res; 2000 May; 15(5):944-51. PubMed ID: 10804025
[TBL] [Abstract][Full Text] [Related]
3. Anabolic effects of recombinant human parathyroid hormone (1 - 84) and synthetic human parathyroid hormone (1 - 34) on the mandibles of osteopenic ovariectomized rats with maxillary molar extraction.
Kawane T; Takahashi S; Saitoh H; Okamoto H; Kubodera N; Horiuchi N
Horm Metab Res; 2002 Jun; 34(6):293-302. PubMed ID: 12173069
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of teriparatide in increasing bone mineral density in postmenopausal women with osteoporosis--an Indian experience.
Sethi BK; Chadha M; Modi KD; Kumar KM; Mehrotra R; Sriram U
J Assoc Physicians India; 2008 Jun; 56():418-24. PubMed ID: 18822620
[TBL] [Abstract][Full Text] [Related]
5. Daily treatment of aged ovariectomized rats with human parathyroid hormone (1-84) for 12 months reverses bone loss and enhances trabecular and cortical bone strength.
Fox J; Miller MA; Newman MK; Metcalfe AF; Turner CH; Recker RR; Smith SY
Calcif Tissue Int; 2006 Oct; 79(4):262-72. PubMed ID: 16969596
[TBL] [Abstract][Full Text] [Related]
6. Effect of strontium ranelate on lumbar spine bone mineral density in women with established osteoporosis previously treated with teriparatide.
Anastasilakis AD; Polyzos SA; Avramidis A; Papatheodorou A; Terpos E
Horm Metab Res; 2009 Jul; 41(7):559-62. PubMed ID: 19204890
[TBL] [Abstract][Full Text] [Related]
7. Effect and safety of intermittent weekly administration of human parathyroid hormone 1-34 in patients with primary osteoporosis evaluated by histomorphometry and microstructural analysis of iliac trabecular bone before and after 1 year of treatment.
Miki T; Nakatsuka K; Naka H; Masaki H; Imanishi Y; Ito M; Inaba M; Morii H; Nishizawa Y
J Bone Miner Metab; 2004; 22(6):569-76. PubMed ID: 15490267
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the efficacy, safety and pharmacokinetic profile of oral recombinant human parathyroid hormone [rhPTH(1-31)NH(2)] in postmenopausal women with osteoporosis.
Henriksen K; Andersen JR; Riis BJ; Mehta N; Tavakkol R; Alexandersen P; Byrjalsen I; Valter I; Nedergaard BS; Teglbjaerg CS; Stern W; Sturmer A; Mitta S; Nino AJ; Fitzpatrick LA; Christiansen C; Karsdal MA
Bone; 2013 Mar; 53(1):160-6. PubMed ID: 23234813
[TBL] [Abstract][Full Text] [Related]
9. Effect of an intermittent weekly dose of human parathyroid hormone (1-34) on osteoporosis: a randomized double-masked prospective study using three dose levels.
Fujita T; Inoue T; Morii H; Morita R; Norimatsu H; Orimo H; Takahashi HE; Yamamoto K; Fukunaga M
Osteoporos Int; 1999; 9(4):296-306. PubMed ID: 10550446
[TBL] [Abstract][Full Text] [Related]
10. A randomized controlled trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential calcitonin to improve bone mass in postmenopausal women with osteoporosis.
Hodsman AB; Fraher LJ; Watson PH; Ostbye T; Stitt LW; Adachi JD; Taves DH; Drost D
J Clin Endocrinol Metab; 1997 Feb; 82(2):620-8. PubMed ID: 9024265
[TBL] [Abstract][Full Text] [Related]
11. Long-term skeletal effects of recombinant human growth hormone (rhGH) alone and rhGH combined with alendronate in GH-deficient adults: a seven-year follow-up study.
Biermasz NR; Hamdy NA; Pereira AM; Romijn JA; Roelfsema F
Clin Endocrinol (Oxf); 2004 May; 60(5):568-75. PubMed ID: 15104559
[TBL] [Abstract][Full Text] [Related]
12. Early changes in urinary cross-linked N-terminal telopeptides of type I collagen level correlate with 1-year response of lumbar bone mineral density to alendronate in postmenopausal Japanese women with osteoporosis.
Iwamoto J; Takeda T; Sato Y; Uzawa M
J Bone Miner Metab; 2005; 23(3):238-42. PubMed ID: 15838627
[TBL] [Abstract][Full Text] [Related]
13. [Effect of raloxifene hydrochloride on bone mineral density, bone metabolism and serum lipids in Chinese postmenopausal women with osteoporosis].
Liu JL; Zhu HM; Huang QR; Zhang ZL; Li HL; Qin YJ; Zhang Y; Wei DL; Lu JH; Liu H; Chen XP; Liu YJ; Ekangaki A; Zheng YM; Diez-Perez A; Harpe K
Zhonghua Yi Xue Za Zhi; 2004 Feb; 84(4):269-73. PubMed ID: 15059505
[TBL] [Abstract][Full Text] [Related]
14. Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis.
Gallagher JC; Rosen CJ; Chen P; Misurski DA; Marcus R
Bone; 2006 Dec; 39(6):1268-75. PubMed ID: 16884968
[TBL] [Abstract][Full Text] [Related]
15. Effects of cyclic vs. daily treatment with human parathyroid hormone (1-34) on murine bone structure and cellular activity.
Iida-Klein A; Lu SS; Cosman F; Lindsay R; Dempster DW
Bone; 2007 Feb; 40(2):391-8. PubMed ID: 17056311
[TBL] [Abstract][Full Text] [Related]
16. Secondary hyperparathyroidism due to hypovitaminosis D affects bone mineral density response to alendronate in elderly women with osteoporosis: a randomized controlled trial.
Barone A; Giusti A; Pioli G; Girasole G; Razzano M; Pizzonia M; Palummeri E; Bianchi G
J Am Geriatr Soc; 2007 May; 55(5):752-7. PubMed ID: 17493196
[TBL] [Abstract][Full Text] [Related]
17. A comparison of the effect of risedronate and etidronate on lumbar bone mineral density in Japanese patients with osteoporosis: a randomized controlled trial.
Fukunaga M; Kushida K; Kishimoto H; Shiraki M; Taketani Y; Minaguchi H; Inoue T; Morita R; Morii H; Yamamoto K; Ohashi Y; Orimo H;
Osteoporos Int; 2002 Dec; 13(12):971-9. PubMed ID: 12459940
[TBL] [Abstract][Full Text] [Related]
18. Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study.
Dempster DW; Cosman F; Kurland ES; Zhou H; Nieves J; Woelfert L; Shane E; Plavetić K; Müller R; Bilezikian J; Lindsay R
J Bone Miner Res; 2001 Oct; 16(10):1846-53. PubMed ID: 11585349
[TBL] [Abstract][Full Text] [Related]
19. Oral hormone therapy with 17beta-estradiol and 17beta-estradiol in combination with norethindrone acetate in the prevention of bone loss in early postmenopausal women: dose-dependent effects.
Greenwald MW; Gluck OS; Lang E; Rakov V
Menopause; 2005; 12(6):741-8. PubMed ID: 16278618
[TBL] [Abstract][Full Text] [Related]
20. [Therapeutic agents for disorders of bone and calcium metabolism. Development of nasal formulation of hPTH (1-34)].
Sato K
Clin Calcium; 2007 Jan; 17(1):64-71. PubMed ID: 17211095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
